Merrem Related Published Studies
Well-designed clinical trials related to Merrem (Meropenem)
Evaluation of the efficacy and safety of intravenous ciprofloxacin versus meropenem in the treatment of postoperative infection. [2011.10.19]
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. [2010.11]
Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. [2010.02]
Microbiological equivalence of serum bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving original meropenem (Meronem) and generic meropenem (Mero). [2010.01]
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. [2009.07]
A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. [2006.08]
Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. [2006.07]
Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. [2006.06]
Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. [2006.04]
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. [2005.10]
Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. [2005.09]
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. [2005.05]
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. [2005.04]
Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. [2005]
Well-designed clinical trials possibly related to Merrem (Meropenem)
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
A protocol for a multicentre randomised controlled trial of continuous
beta-lactam infusion compared with intermittent beta-lactam dosing in critically
ill patients with severe sepsis: the BLING II study. [2013]
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. [2011.02]
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. [2010.08]
[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation] [2009.12]
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. [2008.03]
Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. [2008.03]
Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. [2008.01]
Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials. [2007.11.13]
[Effectiveness of switch therapy for peritonitis] [2007.08]
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia. [2006.10]
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. [2006.02]
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. [2005.07]
Other research related to Merrem (Meropenem)
Pharmacodynamics of meropenem in critically ill patients with
ventilator-associated pneumonia. [2013]
Prospective randomized comparison study of piperacillin/tazobactam and meropenem
for healthcare-associated pneumonia in Japan. [2013]
Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for
patients with hematological disorders and febrile neutropenia. [2013]
Evaluation of the efficacy and safety of intravenous ciprofloxacin versus
meropenem in the treatment of postoperative infection. [2012]
Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. [2011.09.30]
Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. [2011.09]
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. [2011.09]
Efficacy of intratracheal instillation of a meropenem/perfluorochemical suspension in acute lung injury. [2011.08.03]
[Successful treatment of brain stem and thalamic abscesses with high-dose meropenem]. [2011.08]
Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. [2011.07]
[Use of the critical path with the electronic chart system using meropenem, vancomycin, liposome amphotericin B for the febrile neutropenia]. [2011.06]
Successful treatment of Nocardia actinomycetoma with meropenem and amikacin combination therapy. [2011.04]
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. [2011.04]
Optimization of meropenem dosage in the critically ill population based on renal function. [2011.04]
[Successful combination therapy by meropenem and colistin for multi-drug-resistant Pseudomonas aeruginosa infection after allogeneic bone marrow transplantation]. [2011.03]
Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study. [2011.03]
Monitoring of effectiveness and safety of generic formulation of meropenem for treatment of infections at Siriraj Hospital. [2011.02]
[Results of a post-marketing surveillance of meropenem for children]. [2011.02]
Therapeutic effectiveness of a generic versus original meropenem in serious infections. [2011.02]
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. [2010.12]
Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem. [2010.11]
Population pharmacokinetics of meropenem in burn patients. [2010.11]
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. [2010.09.17]
Brain microdialysis study of meropenem in two patients with acute brain injury. [2010.08]
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. [2010.07]
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. [2010.06]
Peritoneal pharmacokinetics and pharmacodynamic target attainment of meropenem in patients undergoing abdominal surgery. [2010.04]
Combined meropenem and linezolid as a systemic treatment for postoperative endophthalmitis. [2010.04]
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. [2010.03.18]
Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. [2010.03]
Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses. [2010.03]
Acute intravascular haemolysis associated with intravenous administration of meropenem in a sixty four year old man. [2010.01]
Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. [2010.01]
Meropenem monotherapy as an empirical treatment of febrile neutropenia in childhood cancer patients. [2010]
Microbiological equivalence of serum bacteriostatic and bactericidal activities
of the sera from healthy volunteers receiving original meropenem (Meronem) and
generic meropenem (Mero). [2010]
Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. [2010]
Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). [2009.12]
In vivo selection of carbapenem-resistant Klebsiella pneumoniae by OmpK36 loss during meropenem treatment. [2009.12]
Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. [2009.12]
Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. [2009.11]
Meropenem pharmacokinetics in the newborn. [2009.09]
Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. [2009.08]
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. [2009.08]
[Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly] [2009.07]
Meropenem-clavulanate: a new strategy for the treatment of tuberculosis? [2009.07]
Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis. [2009.07]
Mortality rate in neonates infected with extended-spectrum beta lactamase-producing Klebsiella species and selective empirical use of meropenem. [2009.06]
Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. [2009.06]
Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin. [2009.04.06]
Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient. [2009.02]
Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit. [2009.01]
Effect of early antibiotic prophylaxis with ertapenem and meropenem in experimental acute pancreatitis in rats. [2009]
Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients. [2009]
The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. [2008.10]
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. [2008.09.15]
Pharmacokinetic and pharmacodynamic properties of meropenem. [2008.09.15]
Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. [2008.09]
[Obtain best usage of meropenem dose in severe infections. Results of an observational multicenter study] [2008.09]
Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. [2008.09]
Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis. [2008.08]
Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem). [2008.07]
[The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients] [2008.07]
The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa. [2008.06]
Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. [2008.06]
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. [2008.05]
Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions. [2008.04]
In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii. [2008.04]
Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. [2008.03]
Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. [2008.03]
Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. [2008.02.23]
Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. [2008.02]
Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. [2008.02]
Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. [2008]
|
